- Todd Shapiro, CEO and Director of Red Light Holland sat down with Brieanna McCutcheon to discuss how the company is working to make a difference
- Red Light Holland’s (TRIP) partner CCrest Laboratories has received Health Canada approval to supply psilocybin for a new special access program
- Last November, Red Light Holland received Health Canada approval to ship its truffles from its farm in the Netherlands to CCrest’s pharmaceutical laboratory in Montreal
- Red Light Holland’s business revolves around the growth and sale of a premium brand of magic truffles to the recreational market in the Netherlands
- Shares of Red Light Holland (TRIP) are currently trading at C$0.135
Todd Shapiro, CEO of Red Light Holland sat down with Brieanna McCutcheon to discuss how the company is working to make a difference.
Algernon Pharmaceuticals’ partner CCrest Lab received approval from Health Canada to supply Psilocybin to the new Special Access Program that would allow patients with conditions that are not treatable by other medication to get access to Psilocybin.
CCrest Laboratories has been working with Shaman Pharma to evaluate Red Light Holland’s naturally occurring psilocybin as a source of active pharmaceutical ingredient for scientific and potentially medical and therapeutic purposes under a Health Canada Controlled Drugs & Substances license. Red Light Holland has received two reports so far, one in November and another in January.
Last November, Red Light Holland shipped its truffles from its farm in the Netherlands to CCrest’s pharmaceutical laboratory in Montreal after receiving Health Canada approval.
Red Light Holland’s business revolves around the production, growth and sale of a premium brand of magic truffles to the recreational market in the Netherlands, in compliance with all applicable laws.
Red Light Holland is strategically based in the Netherlands, an area with a long-standing, established legal magic truffles market.
Shares of Red Light Holland (TRIP) are currently trading at C$0.135.